Loading clinical trials...
Loading clinical trials...
A Phase II Study of Fedratinib and Nivolumab Combination in Patients With Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment
Conditions
Interventions
Fedratinib Oral Capsule [Inrebic]
Nivolumab
Locations
7
Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
University Medicine Greifswald
Greifswald, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Medizinische Hochschule
Hanover, Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Johannes Wesling Klinikum
Minden, Germany
Start Date
June 14, 2022
Primary Completion Date
November 5, 2025
Completion Date
January 15, 2026
Last Updated
April 8, 2026
NCT07357727
NCT06976918
NCT06343805
NCT06327100
NCT06361641
NCT04279847
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions